TY - JOUR
T1 - Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease
T2 - A randomised, double blind, placebo-controlled trial
AU - Chachay, VS
AU - Martin, Jennifer H
AU - Prins, JB
AU - Whitehead, JP
AU - O'Moore-Sullivan, Trisha M
AU - Lee, Paul
AU - Franklin, M
AU - Klein, K
AU - Taylor, PJ
AU - Ferguson, Maree
AU - Coombes, JS
AU - Thomas, Gethin
AU - Cowin, Gary J
AU - Kirkpatrick, C.
AU - MacDonald, graeme
AU - Hickman, Ingrid
PY - 2013
Y1 - 2013
N2 - Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, featuring hepatocyte triglyceride accumulation (steatosis), insulin resistance (IR), dyslipidemia, and increased cardiovascular risk. Potential pharmacological treatment should target both hepatic and cardiometabolic dysregulation. The nutraceutical approach is the use of bioactive food-constituents at pharmacological doses for therapy. Resveratrol is found in grapes, red wine, peanuts and berries and has shown promise in animal models preventing hepatic steatosis, IR,inflammation, oxidative stress, and dyslipidemia, by activating metabolic pathways in a similar manner to calorie restriction. Although resveratrolis widely available over the counter to treat obesity-related metabolic dysfunction, evidence of clinical efficacy and safety in established NAFLD is lacking.
AB - Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, featuring hepatocyte triglyceride accumulation (steatosis), insulin resistance (IR), dyslipidemia, and increased cardiovascular risk. Potential pharmacological treatment should target both hepatic and cardiometabolic dysregulation. The nutraceutical approach is the use of bioactive food-constituents at pharmacological doses for therapy. Resveratrol is found in grapes, red wine, peanuts and berries and has shown promise in animal models preventing hepatic steatosis, IR,inflammation, oxidative stress, and dyslipidemia, by activating metabolic pathways in a similar manner to calorie restriction. Although resveratrolis widely available over the counter to treat obesity-related metabolic dysfunction, evidence of clinical efficacy and safety in established NAFLD is lacking.
M3 - Article
VL - 28
SP - 78
EP - 79
JO - Journal of Gastroenterology and Hepatology (Australia)
JF - Journal of Gastroenterology and Hepatology (Australia)
SN - 0815-9319
IS - Supplement 2
ER -